in this issue
People & Business :: M&A
AstraZeneca rejects Pfizer's latest offer
3:21 PM MDT | May 22, 2014 | Ian Young
AstraZeneca has rejected Pfizer's latest offer to buy AstraZeneca. Pfizer says its offer, which values AstraZeneca at £69 billion ($116 billion), is "final" and cannot be improved. "We have rejected Pfizer's final proposal because it is inadequate and would present significant risks for shareholders while also having serious consequences for the company, our employees, and the life sciences sector in the United Kingdom, Sweden, and the Unted States," says AstraZeneca chairman Leif Johansson. Pfizer's £55/share offer consists of...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee